SAN DIEGO, Feb. 16, 2011 /PRNewswire/ -- MiMedx Group, Inc. (OTC Bulletin Board: MDXG), an integrated developer, manufacturer and marketer of patent protected biomaterial-based products, announced the launch of AmnioFix™, the Company's newest technology platform. MiMedx formally unveiled AmnioFix™ earlier today during the first day of the American Academy of Orthopaedic Surgeons (AAOS) Annual Meeting being held in San Diego, California.
MiMedx recently acquired its AmnioFix™ technology through the acquisition of Surgical Biologics, the leading processor of amniotic tissue and the developer of the patent-pending Purion® process. The Purion® process follows strict guidelines for allograft processing established by the Food and Drug Administration ("FDA") and the American Association of Tissue Banks ("AATB"). While Surgical Biologics' tissue processing procedures are regulated by the FDA, the processed tissue, when implanted for certain medical procedures, is not required to be cleared or approved by the FDA.
AmnioFix™ is processed from the human amniotic membrane through the proprietary Purion® technology to produce an implant that is safe, effective and minimally manipulated. The human amniotic membrane comprises the innermost layer of the placenta, and lines the amniotic cavity.
"With the addition of AmnioFix™, MiMedx now has three very exciting biomaterial platforms to offer to physicians and our distribution networks," said Parker H. "Pete" Petit, Chairman and Chief Executive Officer. "We are pleased to be presenting the many potential applications of the Purion® tissue processing technology for soft tissue repair which should give us offerings that are extremely complementary to our HydroFix™ Vaso Shield product, HydroFix™ Spine Shield product and our planned CollaFix™ products."
|SOURCE MiMedx Group, Inc.|
Copyright©2010 PR Newswire.
All rights reserved